This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Prediction of amyloid-β pathology in amnestic mild cognitive impairment with neuropsychological tests


Bahar-Fuchs, Alex, Villemagne, Victor, Ong, Kevin, Chetélat, Gaël, Lamb, Fiona, Reininger, Cornelia B., Woodward, Michael, Rowe, Christopher C.


Journal Of Alzheimer's Disease: JAD, Volume: 33, No.: 2, Pages.: 451-462

Year of Publication



Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted mainly to research settings. The identification of memory measures that are associated with Aβ is of clinical relevance as this may enhance the confidence in making a diagnosis of MCI due to AD in clinical settings. Forty one persons with amnestic MCI underwent Aβ imaging with (18)F-Florbetaben PET, magnetic resonance imaging, and a comprehensive neuropsychological assessment. All measures of episodic memory were significantly correlated with Aβ burden, but regression analyses revealed a strong and selective association between story recall and Aβ over and beyond the effects of age, education, global cognition, hippocampal volume, or other memory tests. Analyses of sensitivity and specificity of memory measures to detect high versus low Aβ scans suggested that word-list recall performed better when high sensitivity was preferred, whereas story recall performed better when high specificity was preferred. In conclusion, a measure of story recall may increase the confidence in making a diagnosis of MCI due to AD in clinical settings.;


aged, aged, 80 and over, amnesia, amyloidosis, aniline compounds, arabidopsis proteins, biological markers, cyclophilins, diagnostic use, female, fluorine radioisotopes, humans, magnetic resonance imaging, male, memory episodic, metabolism, methods, middle aged, mild cognitive impairment, neuropsychological tests, pathology, positronemission tomography, predictive value of tests, protozoan proteins, radionuclide imaging, regression analysis, reproducibility of results, sensitivity and specificity, standards, stilbenes

Countries of Study


Types of Dementia

Alzheimer’s Disease, Mild Cognitive Impairment (MCI)

Types of Study

Cohort Study

Type of Interventions

Diagnostic Target Identification

Diagnostic Targets

Cognition testing (inc. task driven tests such as clock drawing), Neuroimaging (e.g. MRI, PET, CAT etc.)